Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
Southwest Airlines
EPA
Venezuela
Doug Reinhardt
National emergency
'Walking Dead'
Monsta X
Facebook privacy
F-18 Super Hornets
Amazon
Cuba
Health News
Sept. 14, 2018 / 3:42 PM

FDA approves treatment for 'hairy cell' leukemia

By
HealthDay News
The FDA has approved a treatment for some case of "hairy cell" leukemia, the agency announced on Thursday. Photo by EmilianDanaila/Pixabay

FRIDAY, Sept. 14, 2018 -- Lumoxiti injection has been approved to treat certain instances of relapsed or refractory "hairy cell" leukemia, or HCL, the U.S. Food and Drug Administration said Thursday.

Lumoxiti (moxetumomab pasudotox-tdfk) is among a novel class of drugs called CD22-directed cytotoxins to treat HCL, the agency said. It was approved for adults who have had at least two prior therapies for the disease.

"This therapy is the result of important research conducted by the National Cancer Institute that led to the development and clinical trials of this new type of treatment for patients with this rare blood cancer," said Dr. Richard Pazdur, director of the FDA's Office of Hematology and Oncology Products.

HCL is a slow-growing blood cancer in which the bone marrow makes too many B cells, a type of white blood cell that fights infection, the FDA said. The disease name stems from the extra B cells that appear "hairy" under a microscope.

RELATED Study suggests care could be difference between rural, urban cancer survival rates

Lumoxiti was evaluated in a clinical study of 80 people who had been treated previously for HCL. The most common side effects included injection-related reactions, swelling, nausea, fatigue, headache, fever, constipation, anemia and diarrhea.

The drug's label includes a boxed warning of increased risk for capillary leak syndrome, which is characterized by leaking fluid from tiny blood vessels. The warning also notes increased risk of hemolytic uremic syndrome, an abnormal destruction of red blood cells. Breastfeeding women should not take the drug, the FDA urged.

Lumoxiti is produced by AstraZeneca, based in the United Kingdom.

RELATED Arsenic, existing drug combo could treat cancer, study finds

More information

The FDA has more about this approval.

Copyright © 2018 HealthDay. All rights reserved.

RELATED Tibsovo approved for acute myeloid leukemia
  • Topics
  • Food and Drug Administration
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Number of push-ups men can do in a row may indicate heart health
HPV unlikely to be spread by hands, researchers say
Smoking may hurt body's fight against skin cancer
More primary care physicians in the U.S. may prolong lifespans, study says
Apple-, pear-shaped body determined by genetics, study says

Photo Gallery

 
Palestinians celebrate Valentine's Day

Latest News

5 Americans arrested in Haiti during violent protests
On This Day: U.S. Marines land on Iwo Jima
Famous birthdays for Feb. 19: Roger Goodell, Millie Bobby Brown
UPI Almanac for Tuesday, Feb. 19, 2019
Third migrant dies in Border Patrol custody since December
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy